NXN-188 is a combined neuronal nitric oxide synthase (nNOS) inhibitor and 5-hydroxytryptamine 1B/1D (5-HT1B/1D) receptor agonist. Using preclinical models, we evaluated whether these two unique therapeutic principles have a synergistic effect in attenuating stimulated calcitonin gene-related peptide (CGRP) release, a marker of trigeminal activation.
Methods
We examined the effect of NXN-188 on: (1) KCl-, capsaicin- and resiniferatoxin (RTX)-induced immunoreactive CGRP (iCGRP) release from isolated preparation of rat dura mater, trigeminal ganglion (TG) and trigeminal nucleus caudalis (TNC); and (2) capsaicin- and electrical stimulation (ES)-induced middle meningeal artery (MMA) dilation in a rat closed-cranial window.
Results
NXN-188 inhibited: (1) KCl-stimulated iCGRP release from dura mater (% decrease mean ± SEM, lowest effective concentration) (35 ± 6%, 30 µM), TG (24 ± 11 %, 10 µM) and TNC (40 ± 8%, 10 µM); (2) capsaicin- and RTX-induced iCGRP release from dura mater; and (3) capsaicin- and ES-induced increase in dural artery diameter (32 ± 5%, 3 mg kg−1 intravenous (i.v.) and 36 ± 1%, 10 mg kg−1 i.v.).
Conclusions
NXN-188 inhibits CGRP release from migraine-relevant cephalic tissues. Its effect is most likely mediated via a combination of nNOS-inhibition and 5-HT1B/1D receptor agonism in dura mater while the mechanisms of action for inhibition of CGRP release from TG and TNC have to be investigated further.
MedveRAAndrewsJS. Effects of fixed dose combination of nNOS inhibition and 5HT agonism on progression of migraine with and without aura [abstract PC.23]. Presented at the European Headache and Migraine Trust International Congress 2008. London, UK, 4–7 September 2008. Cephalalgia2009; 29: 126–126.
2.
VillalonCMOlesenJ. The role of CGRP in the pathophysiology of migraine and efficacy of CGRP receptor antagonists as acute antimigraine drugs. Pharmacol Ther2009; 124: 309–323.
3.
OlesenJ. Nitric oxide-related drug targets in headache. Neurotherapeutics2010; 7: 183–190.
4.
MesslingerKLennerzJKEberhardtM. CGRP and NO in the trigeminal system: Mechanisms and role in headache generation. Headache2012; 52: 1411–1427.
LassenLHHaderslevPAJacobsenVB. CGRP may play a causative role in migraine. Cephalalgia2002; 22: 54–61.
7.
LassenLHAshinaMChristiansenI. Nitric oxide synthase inhibition in migraine. Lancet1997; 349: 401–402.
8.
AshinaMLassenLHBendtsenL. Effect of inhibition of nitric oxide synthase on chronic tension-type headache: A randomised crossover trial. Lancet1999; 353: 287–289.
9.
OlesenJDienerHCHusstedtIW. Calcitonin gene-related peptide receptor antagonist BIBN 4096 BS for the acute treatment of migraine. N Engl J Med2004; 350: 1104–1110.
10.
HoTWFerrariMDDodickDW. Efficacy and tolerability of MK-0974 (telcagepant), a new oral antagonist of calcitonin gene-related peptide receptor, compared with zolmitriptan for acute migraine: A randomised, placebo-controlled, parallel-treatment trial. Lancet2008; 372: 2115–2123.
11.
HoTWOlesenJDodickDW. Antimigraine efficacy of telcagepant based on patient's historical triptan response. Headache2011; 51: 64–72.
12.
AkermanSWilliamsonDJKaubeH. Nitric oxide synthase inhibitors can antagonize neurogenic and calcitonin gene-related peptide induced dilation of dural meningeal vessels. Br J Pharmacol2002; 137: 62–68.
13.
NaikAKTandanSKKumarD. Nitric oxide and its modulators in chronic constriction injury-induced neuropathic pain in rats. Eur J Pharmacol2006; 530: 59–69.
14.
YoonYWSungBChungJM. Nitric oxide mediates behavioral signs of neuropathic pain in an experimental rat model. Neuroreport1998; 9: 367–372.
15.
OsborneMGCoderreTJ. Effects of intrathecal administration of nitric oxide synthase inhibitors on carrageenan-induced thermal hyperalgesia. Br J Pharmacol1999; 126: 1840–1846.
16.
BonnefousCPayneJERoppeJ. Discovery of inducible nitric oxide synthase (iNOS) inhibitor development candidate KD7332, part 1: Identification of a novel, potent, and selective series of quinolinone iNOS dimerization inhibitors that are orally active in rodent pain models. J Med Chem2009; 52: 3047–3062.
17.
SymonsKTNguyenPMMassariME. Pharmacological characterization of KLYP961, a dual inhibitor of inducible and neuronal nitric-oxide synthases. J Pharmacol Exp Ther2011; 336: 468–478.
18.
BuzziMGCarterWBShimizuT. Dihydroergotamine and sumatriptan attenuate levels of CGRP in plasma in rat superior sagittal sinus during electrical stimulation of the trigeminal ganglion. Neuropharmacology1991; 30: 1193–1200.
19.
GoadsbyPJEdvinssonL. The trigeminovascular system and migraine: Studies characterizing cerebrovascular and neuropeptide changes seen in humans and cats. Ann Neurol1993; 33: 48–56.
20.
DurhamPLRussoAF. Regulation of calcitonin gene-related peptide secretion by a serotonergic antimigraine drug. J Neurosci1999; 19: 3423–3429.
21.
LimmrothVKatsaravaZLiedertB. An in vivo rat model to study calcitonin gene related peptide release following activation of the trigeminal vascular system. Pain2001; 92: 101–106.
22.
EltorpCTJansen-OlesenIHansenAJ. Release of calcitonin gene-related peptide (CGRP) from guinea pig dura mater in vitro is inhibited by sumatriptan but unaffected by nitric oxide. Cephalalgia2000; 20: 838–844.
23.
AmrutkarDVPlougKBHay-SchmidtA. mRNA expression of 5-hydroxytryptamine 1B, 1D, and 1F receptors and their role in controlling the release of calcitonin gene-related peptide in the rat trigeminovascular system. Pain2012; 153: 830–838.
24.
VaughanDSpeedJMedveR. Safety and pharmacokinetics of NXN-188 after single and multiple doses in five phase I, randomized, double-blind, parallel studies in healthy adult volunteers. Clinical Therapeutics2010; 32: 146–160.
25.
BhattDKPlougKBRamachandranR. Activation of PAR-2 elicits NO-dependent and CGRP-independent dilation of the dural artery. Headache2010; 50: 1017–1030.
26.
GuptaSAmrutkarDVMatajiA. Evidence for CGRP re-uptake in rat dura mater encephali. Br J Pharmacol2010; 161: 1885–1898.
27.
SheykhzadeMGuptaSSorensenT. Characterization of capsaicin induced responses in mice vas deferens: Evidence of CGRP uptake. Eur J Pharmacol2011; 667: 375–382.
28.
HuaXYWongSJinnoS. Pharmacology of calcitonin gene related peptide release from sensory terminals in the rat trachea. Can J Physiol Pharmacol1995; 73: 999–1006.
29.
WilliamsonDJHargreavesRJHillRG. Sumatriptan inhibits neurogenic vasodilation of dural blood vessels in the anaesthetized rat – intravital microscope studies. Cephalalgia1997; 17: 525–531.
30.
PetersenKABirkSDoodsH. Inhibitory effect of BIBN4096BS on cephalic vasodilatation induced by CGRP or transcranial electrical stimulation in the rat. Br J Pharmacol2004; 143: 697–704.
31.
MorikawaTMatsuzawaYMakitaK. Antimigraine drug, zolmitriptan, inhibits high-voltage activated calcium currents in a population of acutely dissociated rat trigeminal sensory neurons. Mol Pain2006; 2: 10–10.
32.
XiaoYRichterJAHurleyJH. Release of glutamate and CGRP from trigeminal ganglion neurons: Role of calcium channels and 5-HT1 receptor signaling. Mol Pain2008; 4: 12–12.
33.
YuXJCutrerFMMoskowitzMA. The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater. Neuropharmacology1997; 36: 83–91.
34.
SkingleMBeattieDTScopesDI. GR127935: A potent and selective 5-HT1D receptor antagonist. Behav Brain Res1996; 73: 157–161.
35.
SelkirkJVScottCHoM. SB-224289 – a novel selective (human) 5-HT1B receptor antagonist with negative intrinsic activity. Br J Pharmacol1998; 125: 202–208.
36.
GasterLMBlaneyFEDaviesS. The selective 5-HT1B receptor inverse agonist 1′-methyl-5-[[2′-methyl-4′-(5-methyl-1,2, 4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]-2,3,6,7-tetrahydro- spiro[furo[2,3-f]indole-3,4′-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo. J Med Chem1998; 41: 1218–1235.
37.
DieterleAFischerMJLinkAS. Increase in CGRP- and nNOS-immunoreactive neurons in the rat trigeminal ganglion after infusion of an NO donor. Cephalalgia2011; 31: 31–42.
38.
Knyihar-CsillikEVecseiL. Effect of a nitric oxide donor on nitroxergic nerve fibers in the rat dura mater. Neurosci Lett1999; 260: 97–100.
39.
JancsoNJancso-GaborASzolcsanyiJ. Direct evidence for neurogenic inflammation and its prevention by denervation and by pretreatment with capsaicin. Br J Pharmacol Chemother1967; 31: 138–151.
40.
HolzerP. Local effector functions of capsaicin-sensitive sensory nerve endings: Involvement of tachykinins, calcitonin gene-related peptide and other neuropeptides. Neuroscience1988; 24: 739–768.
41.
SzallasiABlumbergPM. Resiniferatoxin, a phorbol-related diterpene, acts as an ultrapotent analog of capsaicin, the irritant constituent in red pepper. Neuroscience1989; 30: 515–520.
42.
GuptaSLozano-CuencaJVillalónCM. Pharmacological characterisation of capsaicin-induced relaxations in human and porcine isolated arteries. Naunyn Schmiedebergs Arch Pharmacol2007; 375: 29–38.
LoydDRWeissGHenryMA. Serotonin increases the functional activity of capsaicin-sensitive rat trigeminal nociceptors via peripheral serotonin receptors. Pain2011; 152: 2267–2276.
45.
GuptaSBhattDKBoniLJ. Improvement of the closed cranial window model in rats by intracarotid infusion of signalling molecules implicated in migraine. Cephalalgia2010; 30: 27–36.
46.
AkermanSKaubeHGoadsbyPJ. Anandamide acts as a vasodilator of dural blood vessels in vivo by activating TRPV1 receptors. Br J Pharmacol2004; 142: 1354–1360.
47.
Muñoz-IslasELozano-CuencaJGonzález-HernándezA. Spinal sumatriptan inhibits capsaicin-induced canine external carotid vasodilatation via 5-HT1B rather than 5-HT1D receptors. Eur J Pharmacol2009; 615: 133–138.
48.
Sánchez-LópezACenturiónDVázquezE. Further characterization of the 5-HT1 receptors mediating cardiac sympatho-inhibition in pithed rats: Pharmacological correlation with the 5-HT1B and 5-HT1D subtypes. Naunyn Schmiedebergs Arch Pharmacol2004; 369: 220–227.
49.
González-HernándezAMuñoz-IslasELozano-CuencaJ. Activation of 5-HT1B receptors inhibits the vasodepressor sensory CGRPergic outflow in pithed rats. Eur J Pharmacol2010; 637: 131–137.
50.
González-HernándezAManrique-MaldonadoGLozano-CuencaJ. The 5-HT(1) receptors inhibiting the rat vasodepressor sensory CGRPergic outflow: Further involvement of 5-HT(1F), but not 5-HT(1A) or 5-HT(1D), subtypes. Eur J Pharmacol2011; 659: 233–243.
51.
MedveRALateganTW. A phase 2 multicenter, randomized, double-blind, parallel-group, placebo-controlled study of NXN-188 dihydrochloride in acute migraine without aura [abstract 190]. Presented at the 2nd European Headache and Migraine Trust International Congress 2010. Nice, France, 28–31 October 2010. J Headache Pain2010; 11: 38–38.
